These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 1712305

  • 1. Injection of tachykinins and selective neurokinin receptor ligands into the substantia nigra reticulata increases striatal dopamine and 5-hydroxytryptamine metabolism.
    Humpel C, Saria A, Regoli D.
    Eur J Pharmacol; 1991 Mar 19; 195(1):107-14. PubMed ID: 1712305
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.
    Picard P, Regoli D, Couture R.
    Br J Pharmacol; 1994 May 19; 112(1):240-9. PubMed ID: 7518304
    [Abstract] [Full Text] [Related]

  • 3. Intranigral injection of selective neurokinin-1 and neurokinin-3 but not neurokinin-2 receptor agonists biphasically modulate striatal dopamine metabolism but not striatal preprotachykinin-A mRNA in the rat.
    Humpel C, Saria A.
    Neurosci Lett; 1993 Jul 23; 157(2):223-6. PubMed ID: 7694197
    [Abstract] [Full Text] [Related]

  • 4. Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation.
    Lindefors N, Brodin E, Tossman U, Segovia J, Ungerstedt U.
    Exp Brain Res; 1989 Jul 23; 74(3):527-34. PubMed ID: 2468514
    [Abstract] [Full Text] [Related]

  • 5. Modulation of cardiac activity by tachykinins in the rat substantia nigra.
    Lessard A, Couture R.
    Br J Pharmacol; 2001 Dec 23; 134(8):1749-59. PubMed ID: 11739252
    [Abstract] [Full Text] [Related]

  • 6. Differential effects of tachykinins injected intranigrally on striatal dopamine metabolism.
    Tan DP, Tsou K.
    J Neurochem; 1988 Nov 23; 51(5):1333-7. PubMed ID: 2459306
    [Abstract] [Full Text] [Related]

  • 7. Effects of intranigral substance P and neurokinin A on striatal dopamine release--I. Interactions with substance P antagonists.
    Reid MS, Herrera-Marschitz M, Hökfelt T, Ohlin M, Valentino KL, Ungerstedt U.
    Neuroscience; 1990 Nov 23; 36(3):643-58. PubMed ID: 1700329
    [Abstract] [Full Text] [Related]

  • 8. Intranigral substance P modulation of striatal dopamine: interaction with N-terminal and C-terminal substance P fragments.
    Reid MS, Herrera-Marschitz M, Terenius L, Ungerstedt U.
    Brain Res; 1990 Sep 03; 526(2):228-34. PubMed ID: 1701682
    [Abstract] [Full Text] [Related]

  • 9. Evidence that tachykinins relax the guinea-pig trachea via nitric oxide release and by stimulation of a septide-insensitive NK1 receptor.
    Figini M, Emanueli C, Bertrand C, Javdan P, Geppetti P.
    Br J Pharmacol; 1996 Mar 03; 117(6):1270-6. PubMed ID: 8882625
    [Abstract] [Full Text] [Related]

  • 10. Study of SR 142801, a new potent non-peptide NK3 receptor antagonist on cardiovascular responses in conscious guinea-pig.
    Roccon A, Marchionni D, Nisato D.
    Br J Pharmacol; 1996 Jul 03; 118(5):1095-102. PubMed ID: 8818331
    [Abstract] [Full Text] [Related]

  • 11. Demonstration of a 'septide-sensitive' inflammatory response in rat skin.
    Ahluwalia A, Giuliani S, Maggi CA.
    Br J Pharmacol; 1995 Oct 03; 116(4):2170-4. PubMed ID: 8564245
    [Abstract] [Full Text] [Related]

  • 12. Neurokinin receptors (NK1, NK2) in the mouse: a pharmacological study.
    Nsa Allogho S, Nguyen-Le XK, Gobeil F, Pheng LH, Regoli D.
    Can J Physiol Pharmacol; 1997 Jun 03; 75(6):552-7. PubMed ID: 9276127
    [Abstract] [Full Text] [Related]

  • 13. Receptors mediating tachykinin-evoked depolarisations of neurons in the neonatal rat spinal cord.
    Fox AJ, Naeem S, Patel IA, Walpole C, Urbán L.
    Acta Biol Hung; 1996 Jun 03; 47(1-4):129-44. PubMed ID: 9123986
    [Abstract] [Full Text] [Related]

  • 14. The selective NK3 receptor agonist senktide excites a subpopulation of dopamine-sensitive neurones in the rat substantia nigra pars compacta in vitro.
    Keegan KD, Woodruff GN, Pinnock RD.
    Br J Pharmacol; 1992 Jan 03; 105(1):3-5. PubMed ID: 1375857
    [Abstract] [Full Text] [Related]

  • 15. Intranigral substance P stimulation of striatal dopamine release is inhibited by spantide II: a new tachykinin antagonist without apparent neurotoxicity.
    Reid MS, Hökfelt T, Herrera-Marschitz M, Håkanson R, Feng DM, Folkers K, Goldstein M, Ungerstedt U.
    Brain Res; 1990 Nov 05; 532(1-2):175-81. PubMed ID: 1704289
    [Abstract] [Full Text] [Related]

  • 16. Modulation of excitatory amino acid responses by tachykinins and selective tachykinin receptor agonists in the rat spinal cord.
    Cumberbatch MJ, Chizh BA, Headley PM.
    Br J Pharmacol; 1995 Jul 05; 115(6):1005-12. PubMed ID: 7582496
    [Abstract] [Full Text] [Related]

  • 17. Central tachykinin NK3 receptors in the inhibitory action on the rat colonic propulsion of a new tachykinin, PG-KII.
    Broccardo M, Improta G, Tabacco A.
    Eur J Pharmacol; 1999 Jul 02; 376(1-2):67-71. PubMed ID: 10440091
    [Abstract] [Full Text] [Related]

  • 18. Neurokinin receptors differentially mediate endogenous acetylcholine release evoked by tachykinins in the neostriatum.
    Arenas E, Alberch J, Perez-Navarro E, Solsona C, Marsal J.
    J Neurosci; 1991 Aug 02; 11(8):2332-8. PubMed ID: 1651375
    [Abstract] [Full Text] [Related]

  • 19. Diverse effects of tachykinins on luteinizing hormone release in male rats: mechanism of action.
    Kalra PS, Sahu A, Bonavera JJ, Kalra SP.
    Endocrinology; 1992 Sep 02; 131(3):1195-201. PubMed ID: 1380435
    [Abstract] [Full Text] [Related]

  • 20. Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway.
    Li SJ, Sivam SP, McGinty JF, Huang YS, Hong JS.
    J Pharmacol Exp Ther; 1987 Nov 02; 243(2):792-8. PubMed ID: 2445959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.